Company: ARTL
Filing Date: 2025-08-20
Form Type: 8-K
Source: 0001640334-25-001570
Chunk: 2

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-08-20
Form: 8-K
Item: Item 9.01
Chunk 2
---
Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

  Exhibit No.      Description                                                                                                               
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
         10.1      Form of Termination and Mutual Release Agreement by and between Artelo Biosciences, Inc. and the investors named therein  
         10.2      Termination Agreement by and between Artelo Biosciences, Inc. and ABK Labs, Inc., dated August 19, 2025                   

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  Date: August 20, 2025      ARTELO BIOSCIENCES, INC.                                             
 ──────────────────────────────────────────────────────────────────────────────────────────────────
                             /s/ Gregory D. Gorgas                                                
                             Name:                         Gregory D. Gorgas                      
                             Title:                        Chief Executive Officer and President  

   3